Compare SNOW & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNOW | KVUE |
|---|---|---|
| Founded | 2012 | 2022 |
| Country | United States | United States |
| Employees | N/A | 22000 |
| Industry | Computer Software: Prepackaged Software | Specialty Chemicals |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9B | 33.6B |
| IPO Year | 2020 | 2023 |
| Metric | SNOW | KVUE |
|---|---|---|
| Price | $140.47 | $17.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 43 | 11 |
| Target Price | ★ $248.62 | $19.45 |
| AVG Volume (30 Days) | 7.1M | ★ 15.5M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.75% |
| EPS Growth | N/A | ★ 40.74 |
| EPS | N/A | ★ 0.76 |
| Revenue | $4,683,946,000.00 | ★ $15,124,000,000.00 |
| Revenue This Year | $28.57 | $4.85 |
| Revenue Next Year | $23.41 | $2.63 |
| P/E Ratio | ★ N/A | $23.01 |
| Revenue Growth | ★ 29.16 | N/A |
| 52 Week Low | $118.30 | $14.02 |
| 52 Week High | $280.67 | $25.17 |
| Indicator | SNOW | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 50.07 |
| Support Level | $118.30 | $17.20 |
| Resistance Level | $157.84 | $17.74 |
| Average True Range (ATR) | 8.90 | 0.32 |
| MACD | 1.67 | 0.04 |
| Stochastic Oscillator | 55.87 | 72.73 |
Snowflake Inc Founded in 2012, Snowflake is a fully managed platform that consolidates data hosted on different public clouds for centralized analytics and governance. Snowflakes cloud-native architecture allows users to independently scale the compute and storage layers, providing customers with optimized performance at lower costs. The companies data lake and data warehouse products support a variety of use cases, including business analytics, data engineering, and artificial intelligence. Snowflake is widely used by Fortune 2000 companies in financial services, media, and retail sectors.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.